Nothing Special   »   [go: up one dir, main page]

NL300998I2 - Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan - Google Patents

Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan Download PDF

Info

Publication number
NL300998I2
NL300998I2 NL300998C NL300998C NL300998I2 NL 300998 I2 NL300998 I2 NL 300998I2 NL 300998 C NL300998 C NL 300998C NL 300998 C NL300998 C NL 300998C NL 300998 I2 NL300998 I2 NL 300998I2
Authority
NL
Netherlands
Prior art keywords
lusutrombopag
solvates
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
NL300998C
Other languages
English (en)
Other versions
NL300998I1 (nl
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NL300998I1 publication Critical patent/NL300998I1/nl
Publication of NL300998I2 publication Critical patent/NL300998I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL300998C 2007-07-31 2019-06-27 Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan NL300998I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007198590 2007-07-31
PCT/JP2008/063541 WO2009017098A1 (ja) 2007-07-31 2008-07-29 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体

Publications (2)

Publication Number Publication Date
NL300998I1 NL300998I1 (nl) 2019-07-03
NL300998I2 true NL300998I2 (nl) 2019-08-28

Family

ID=40304328

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300998C NL300998I2 (nl) 2007-07-31 2019-06-27 Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan

Country Status (21)

Country Link
US (2) US8530668B2 (nl)
EP (1) EP2184279B1 (nl)
JP (1) JP5164181B2 (nl)
KR (1) KR20100027243A (nl)
CN (4) CN103393678A (nl)
AU (1) AU2008283357B2 (nl)
BR (1) BRPI0814891A2 (nl)
CA (1) CA2694567C (nl)
CY (1) CY1116190T1 (nl)
DK (1) DK2184279T3 (nl)
ES (1) ES2528196T3 (nl)
FR (1) FR19C1043I2 (nl)
HR (1) HRP20150062T1 (nl)
MX (1) MX2010001082A (nl)
NL (1) NL300998I2 (nl)
PL (1) PL2184279T3 (nl)
PT (1) PT2184279E (nl)
RU (1) RU2476429C2 (nl)
SI (1) SI2184279T1 (nl)
TW (1) TWI422371B (nl)
WO (1) WO2009017098A1 (nl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564008B (zh) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
JP6202620B2 (ja) * 2012-06-29 2017-09-27 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する化合物を含有する医薬組成物
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
CN105412930A (zh) * 2015-08-07 2016-03-23 军事医学科学院华南干细胞与再生医学研究中心 血小板生成素受体激动剂在促进造血干细胞归巢中的用途
JP6168579B1 (ja) * 2016-02-12 2017-07-26 塩野義製薬株式会社 重度の肝機能障害のある患者のためのルストロンボパグを含有する血小板産生促進剤
CN106083759B (zh) * 2016-06-15 2022-02-15 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
JP2019529342A (ja) * 2016-09-08 2019-10-17 四川科倫博泰生物医薬股▲フン▼有限公司Sichuan Kelun−Biotech Biopharmaceutical Co., Ltd. 新型2−アミドチアゾール誘導体、及びその製造方法と用途
CN106565625B (zh) * 2016-11-04 2018-01-30 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法
CN109311831B (zh) * 2017-02-14 2021-07-09 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法
CN109970678B (zh) * 2017-12-28 2024-03-08 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途
WO2019233328A1 (zh) 2018-06-08 2019-12-12 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法
CN113164455A (zh) * 2018-12-04 2021-07-23 盐野义制药株式会社 难溶性药物的固体分散体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2055712A1 (en) * 1995-06-07 2009-05-06 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
JPH1072492A (ja) 1996-09-02 1998-03-17 Hokuriku Seiyaku Co Ltd ペプチド化合物
JPH10287634A (ja) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
JPH111477A (ja) 1997-06-12 1999-01-06 Hokuriku Seiyaku Co Ltd 1,4−ベンゾジアゼピン誘導体及びその用途
JPH11152276A (ja) 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU6023300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CN1516696A (zh) * 2001-01-26 2004-07-28 盐野义制药株式会社 对血小板生成素受体具有激动作用的卤素化合物
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
ES2610611T3 (es) 2002-01-18 2017-04-28 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
JP4317818B2 (ja) 2002-09-30 2009-08-19 アステラス製薬株式会社 2−アシルアミノチアゾール誘導体の新規な塩
US6737382B1 (en) * 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CN1835948B (zh) 2003-07-17 2010-05-26 安斯泰来制药有限公司 2-酰基氨基噻唑衍生物或其盐
CN103130739B (zh) * 2003-08-12 2015-09-16 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
CN1898221A (zh) * 2003-09-06 2007-01-17 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
US8515798B2 (en) 2005-09-27 2013-08-20 Accenture Global Services Gmbh Closed-loop supply chain in the paper packaging sector
JP2009514941A (ja) 2005-11-08 2009-04-09 アステラス製薬株式会社 血小板減少症を治療する化合物および方法

Also Published As

Publication number Publication date
CN103393678A (zh) 2013-11-20
CN103450110A (zh) 2013-12-18
FR19C1043I2 (fr) 2020-04-03
US20130217885A1 (en) 2013-08-22
CY1116190T1 (el) 2017-02-08
CN103396313A (zh) 2013-11-20
WO2009017098A1 (ja) 2009-02-05
PT2184279E (pt) 2015-02-05
EP2184279A1 (en) 2010-05-12
US8530668B2 (en) 2013-09-10
CA2694567A1 (en) 2009-02-05
JPWO2009017098A1 (ja) 2010-10-21
PL2184279T3 (pl) 2015-04-30
AU2008283357B2 (en) 2011-08-11
FR19C1043I1 (nl) 2019-08-09
EP2184279A4 (en) 2011-11-02
JP5164181B2 (ja) 2013-03-13
CN103450110B (zh) 2015-12-09
CN101809008B (zh) 2013-09-18
US20100267783A1 (en) 2010-10-21
TWI422371B (zh) 2014-01-11
AU2008283357A1 (en) 2009-02-05
TW200914000A (en) 2009-04-01
CN103396313B (zh) 2015-05-13
ES2528196T3 (es) 2015-02-05
US8889722B2 (en) 2014-11-18
EP2184279B1 (en) 2014-11-12
BRPI0814891A2 (pt) 2015-08-18
NL300998I1 (nl) 2019-07-03
RU2476429C2 (ru) 2013-02-27
KR20100027243A (ko) 2010-03-10
RU2010107169A (ru) 2011-09-10
MX2010001082A (es) 2010-03-01
CA2694567C (en) 2013-04-23
HRP20150062T1 (hr) 2015-04-10
SI2184279T1 (sl) 2015-04-30
DK2184279T3 (en) 2015-01-26
CN101809008A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
NL300998I2 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
NL301090I1 (nl) Entrectinib, dan wel tautomeren, of farmaceutisch aanvaardbare zouten daarvan
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0813836A2 (pt) Derivados pirazólicos
CR10562A (es) Nuevos derivados de piridazina
DK1810702T3 (da) Forbedret kirurgisk kassette
DK2144905T3 (da) Terapeutiske midler
ATE518837T1 (de) Indazolamidderivate
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0817964A2 (pt) Implante cirúrgico
ATE448431T1 (de) Chirurgische kassette
ATE519760T1 (de) Isoxazolimidazolderivate
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
SMT201600041B (it) Agenti terapeutici 713
DE602008001249D1 (de) Indol-2-yl-piperazin-1-yl-methanon-derivate
DK2121138T3 (da) Terapeutiske anvendelser af eslicarbazepin
DK2167469T3 (da) Sulfonylquinolinderivater